Supernus Pharmaceuticals SUPN Free cash flow yield
Free cash flow yield at other companies
Other financials
Where this comes from
Calculated from Supernus Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The official record: Supernus Pharmaceuticals’s 10-Q, filed August 5, 2025, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's free cash flow yield.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's free cash flow yield?
- Supernus Pharmaceuticals (SUPN) reported free cash flow yield of 10.5% in Q2 2025.
- How has Supernus Pharmaceuticals's free cash flow yield changed year-over-year?
- Supernus Pharmaceuticals's free cash flow yield decreased by 0.5% year-over-year, from 10.5% to 10.5%.
- What is the long-term trend for Supernus Pharmaceuticals's free cash flow yield?
- Over 2 years (2020 to 2024), Supernus Pharmaceuticals's free cash flow yield has grown at a -8.0% compound annual growth rate (CAGR), from 10.1% to 8.6%.
- What does free cash flow yield mean?
- Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.